Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients

American Journal of Transplantation

Volumn 14, Issue 4, 2014, Pages 867-875

  Del Bello, A ^a,b   Congy Jolivet, N ^a,b   Muscari, F ^a,b   Lavayssiere L ^a   Esposito, L ^a   Cardeau Desangles, I ^a   Guitard, J ^a   Dorr G ^a,b   Suc, B ^a,b   Duffas, J P ^a   Alric, L ^b,c   Bureau, C ^b,c   Danjoux, M ^c   Guilbeau Frugier, C ^a,b   Blancher, A ^a,b   Rostaing, L ^a,b,c   Kamar, N ^a,b,c  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

Author keywords

Donor specific antibodies; incidence; liver transplantation; prevalence; steroid free

Indexed keywords

ALPHA INTERFERON; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DONOR SPECIFIC HLA ANTIBODY; HLA ANTIBODY; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIBODY; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HEPATITIS E; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMAPHERESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETRANSPLANTATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SEROPREVALENCE; ADOLESCENT; AGED; BLOOD; COMPLICATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; INCIDENCE; LIVER CIRRHOSIS; LIVER DISEASES; MORTALITY; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; REOPERATION; RISK FACTOR; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; INCIDENCE; ISOANTIBODIES; LIVER CIRRHOSIS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84897111123     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12651     Document Type: Article

References (26)

1. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
2. Haas M., Pathologic features of antibody-mediated rejection in renal allografts: An expanding spectrum. Curr Opin Nephrol Hypertens 2012; 21: 264-271.
3. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011; 11: 1792-1802.
4. Morrell MR, Patterson GA, Trulock EP, Hachem RR., Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2009; 28: 96-100.
5. Hodges AM, Lyster H, McDermott A, et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 2012; 93: 650-656.
6. Ogura K, Koyama H, Takemoto S, Terasaki PI, Busuttil RW., Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24: 1465.
7. Takaya S, Duquesnoy R, Iwaki Y, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23: 396-3399.
8. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
9. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
10. O'Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973-980.
11. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
12. Musat AI, Pigott CM, Ellis TM, et al. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation. Liver Transpl 2013; 19: 1132-1141.
13. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
14. Bedossa P, Poynard T., An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
15. Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M., Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23: 858-859.
16. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
17. O'Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
18. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Post liver transplant. Am J Transplant 2011; 11: 1868-1876.
19. Kaneku H, O'Leary JG, Banuelos M, et al. De novo Donor Specific HLA-Antibodies decrease patient and graft survival in liver transpant recipients. Am J Transplant 2013; 13: 1541-1548.
20. Chaudhuri A, Ozawa M, Everly MJ, et al. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 2013; 24: 655-664.
21. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
22. Wilson CH, Agarwal K, Carter V, et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006; 82: 988-989.
23. Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029.
24. Kamar N, Lavayssière L, Muscari F, et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15: 3426-3430.
25. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526-2531.
26. Briggs D, Adams DH., Antibody-associated rejection in liver transplantation: Keep on knocking and the door will be opened to you. Am J Transplant 2011; 11: 1767-1768.